We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Quethera

News List

Astellas Pharma acquires Quethera for $108.5m pharmaceutical-technology
August 15, 2018
Japan-based Astellas Pharma has acquired British gene therapy company Quethera, which primarily develops new treatments for ocular diseases such as glaucoma.
Astellas acquires gene therapy group Quethera in £85 million deal pharmafile
August 14, 2018
The Japanese company Astellas Pharma has acquired British gene therapy group Quethera in a deal worth up to £85 million.
Astellas acquires Quethera for up to £85M biospectrumasia
August 13, 2018
Through this transaction, Astellas has acquired Quethera's ophthalmic gene therapy program, which uses a recombinant adeno-associated viral vector system (rAAV) to introduce therapeutic genes into target retinal cells for the treatment of glaucoma.
Astellas absorbs U.K. ocular gene therapy player Quethera fiercebiotech
August 13, 2018
Japan’s Astellas Pharma has delved deeper into the gene therapy sector, picking up U.K. specialist Quethera for around $109 million.